Medical device maker BenQ Medical Technology, to cope with the impact from US-China trade disputes and the coronavirus pandemic, will continue expanding business operation through seeking additional strategic partners, according to company chairman Peter Chen.
For 2020, BenQ Medical is mainly focusing on the development of medical devices, medical consumable materials and medical care services and is collaborating with its strategic partners to penetrate into the industry, Chen said.
BenQ Medical has already begun selling in-house developed portable diagnostic ultrasound devices in Taiwan and is also exporting the devices to European and Southeast Asian countries. In addition, the company has also developed adjustable tables and LED lamps for use in surgical operation as well as medical display monitors.
BenQ Medical has also marketed products produced by affiliates, including intra-oral scanners, dental implants and dental implantation software developed by BenQ AB DentCare, hearing aids developed by BenQ Hearing Solution, needle-free injection devices, liquid infusion sets, medical gloves and artificial noses developed by Lily Medical.
BenQ Medical's shareholders at a recent meeting approved the distribution of a cash dividend per share of NT$1.35 (US$0.045) for 2019, accounting for 79.88% of the corresponding net EPS of NT$1.69.
BenQ Medical has reported consolidated revenues of NT$97.6 million for May, decreasing 6.57% on month and 12.38% on year, and those of NT$502.6 million for January-May, slipping 8.79% on year.
BenQ Medical Technology chairman Peter Chen
Photo: Shih-min Fu, Digitimes, June 2020
Article translated by Adam Hwang
